Eg5 inhibition with LGI-147 demonstrated promising in vitro and in vivo efficacy against HCC cells, suggesting that Eg5 is a potential clinical prognostic factor and therapeutic target for HCC. The gene discussed is KIF11; the disease is hepatocellular carcinoma.